MedTrace Logo

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

NCT03418922 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-06-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Lenvatinib

Specified doses will be administered orally on specified days.

DRUG

Nivolumab

Specified doses will be administered intravenously on specified days.

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • Eisai Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-16
Primary Completion
2022-12-28
Completion
2022-12-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418922 on ClinicalTrials.gov